Ocugen Inc. presented a gene therapy pipeline update at the Piper Sandler Virtual Ophthalmology Day on July 10, 2026.
The company's strategy focuses on one-time treatments for three late-stage clinical programs. Management reported positive efficacy signals for retinitis pigmentosa, Stargardt disease, and geographic atrophy.
All three programs have recorded zero drug-related serious adverse events to date. Ocugen targets Biologics License Application (BLA) filings for retinitis pigmentosa and Stargardt disease in 2025. The company anticipates a BLA filing for geographic atrophy in 2028.